Induce Biologics

Induce Biologics, founded in 2015, is a private, commercial-stage company focused on advancing bone regeneration through its proprietary NMP technology. The platform processes demineralized bone matrix to enhance the bioavailability of inherent growth factors, positioning its products as a potentially more natural and effective alternative to traditional bone grafts and synthetic biologics. With a seasoned leadership team boasting decades of experience in orthobiologics, the company is commercializing its product family in the substantial bone graft substitute market. Its key challenge lies in gaining market share against established competitors and demonstrating superior clinical outcomes.

Natural Matrix Protein (NMP): A proprietary process that treats human demineralized bone matrix to 'unlock' and enhance the bioavailability of the native growth factors (e.g., BMPs) naturally present within the bone, aiming to replicate and amplify the body's own osteoregenerative healing cascade.

Induce Biologics competes in the crowded allograft and orthobiologics space, facing off against major players like Medtronic, Stryker, Zimmer Biomet, and RTI Surgical, which offer a wide range of DBM, synthetic, and cell-based products. Its differentiation is based on the enhanced bioavailability claim of its NMP process versus standard DBMs, positioning it as a premium allograft option.